NCT06165367 Hyaluronan-enriched Medium and Euploid Blastocyst Transfers
| NCT ID | NCT06165367 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ART Fertility Clinics LLC |
| Condition | Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 783 participants |
| Start Date | 2024-01-15 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 783 participants in total. It began in 2024-01-15 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule. However, none of previous studies included preimplantation genetic testing for aneuploidy (PGT-A) embryos. In order to investigate the impact of this hyaluronan-enriched on pregnancy outcomes, it is essential to evaluate its efficacy on euploid-only embryo transfers. The aim of the present study is to evaluate whether a short period of exposure of euploid blastocysts to EmbryoGlue prior to and during transfer positively impact on pregnancy outcomes of frozen embryo transfer (FET) cycles.
Eligibility Criteria
Inclusion Criteria: * All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A. * Rank of randomization based on embryo quality. * Only hormonal replacement theraphy (HRT) cycle regimen. * Women aged 18 years to 46 years. * Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer. * All sperm samples. * BMI between 18 and 35. Exclusion Criteria: * FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR). * FET cycles with mosaic / aneuploid blastocysts. * FET cycles with unknown outcome. * FET cycles with Day 6 or Day 7 biopsied blastocysts. * FET with patients' endometrium preparation with treatments other than HRT. * FET where PGT-A was performed for gender selection.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06165367 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 46 Years, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06165367 currently recruiting?
Yes, NCT06165367 is actively recruiting participants. Contact the research team at daniela.nogueira@artfertilityclinics.com for enrollment information.
Where is the NCT06165367 trial being conducted?
This trial is being conducted at Abu Dhabi, United Arab Emirates.
Who is sponsoring the NCT06165367 clinical trial?
NCT06165367 is sponsored by ART Fertility Clinics LLC. The trial plans to enroll 783 participants.